A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
At a glance
- Drugs Olokizumab (Primary) ; Adalimumab; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms CREDO 2
- Sponsors R-Pharm
- 07 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 30 Mar 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2019.